<DOC>
	<DOCNO>NCT02750956</DOCNO>
	<brief_summary>The primer aim study determine serum gingival crevicular fluid ( GCF ) endocan level periodontal disease pathogenesis support vascular endothelial growth factor ( VEGF ) tumor necrosis factor alpha ( TNF-α ) level .</brief_summary>
	<brief_title>Endocan , VEGF TNF-alpha Levels Periodontal Disease After Treatment</brief_title>
	<detailed_description>The study consist three group : periodontally healthy individual ( group 1 ; n = 20 ) , individual generalize chronic periodontitis ( group 2 ; n = 20 ) , patient chronic periodontitis treat scale root planing ( SRP ) consider Group 3 . Clinical measurement record ; GCF serum sample obtain participant 6 week therapy . Endocan , VEGF-A TNF-α level measure enzyme-linked immunosorbent assay .</detailed_description>
	<mesh_term>Periodontal Diseases</mesh_term>
	<mesh_term>Gingival Diseases</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Group 1 No bone attachment loss , GI=0 , PPD≤3mm , CAL≤3mm Systematically healthy patient Group 2 GI &gt; 1 , PPD≥5mm , CAL≥5mm alveolar bone loss radiographically . Systematically healthy patient Aggressive Periodontitis , Oral pathology , Patients systemic disease , Pregnant woman lactation period , Patients smoke habit take medication Patients receive periodontal therapy last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>endocan protein</keyword>
	<keyword>VEGF A</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>treatment</keyword>
</DOC>